- Home
- MAX vs PLRX Comparison
MAX vs PLRX Comparison
Compare MAX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- PLRX
- Stock Information
- Founded
- MAX 2014
- PLRX 2015
- Country
- MAX United States
- PLRX United States
- Employees
- MAX N/A
- PLRX N/A
- Industry
- MAX Industrial Machinery/Components
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- PLRX Health Care
- Exchange
- MAX Nasdaq
- PLRX Nasdaq
- Market Cap
- MAX 551.1M
- PLRX 93.3M
- IPO Year
- MAX 2020
- PLRX 2020
- Fundamental
- Price
- MAX $11.54
- PLRX $1.50
- Analyst Decision
- MAX Buy
- PLRX Hold
- Analyst Count
- MAX 6
- PLRX 11
- Target Price
- MAX $17.00
- PLRX $3.79
- AVG Volume (30 Days)
- MAX 646.3K
- PLRX 773.1K
- Earning Date
- MAX 10-29-2025
- PLRX 11-06-2025
- Dividend Yield
- MAX N/A
- PLRX N/A
- EPS Growth
- MAX N/A
- PLRX N/A
- EPS
- MAX N/A
- PLRX N/A
- Revenue
- MAX $1,123,093,000.00
- PLRX N/A
- Revenue This Year
- MAX $31.14
- PLRX N/A
- Revenue Next Year
- MAX $9.79
- PLRX N/A
- P/E Ratio
- MAX N/A
- PLRX N/A
- Revenue Growth
- MAX 64.86
- PLRX N/A
- 52 Week Low
- MAX $7.33
- PLRX $1.10
- 52 Week High
- MAX $13.85
- PLRX $15.80
- Technical
- Relative Strength Index (RSI)
- MAX 42.31
- PLRX 41.22
- Support Level
- MAX $12.46
- PLRX $1.45
- Resistance Level
- MAX $13.49
- PLRX $1.82
- Average True Range (ATR)
- MAX 0.57
- PLRX 0.12
- MACD
- MAX -0.16
- PLRX -0.02
- Stochastic Oscillator
- MAX 2.13
- PLRX 15.07
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.